CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $105,000 | – | 3,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,913,749,385 | 28.70% |
| Perceptive Advisors | 10,088,385 | $320,709,759 | 9.28% |
| Affinity Asset Advisors, LLC | 550,000 | $17,484,500 | 6.11% |
| Finepoint Capital LP | 492,545 | $15,658,006 | 5.42% |
| Paradigm Biocapital Advisors LP | 1,868,946 | $59,413,793 | 4.59% |
| BOONE CAPITAL MANAGEMENT LLC | 300,000 | $9,537,000 | 3.42% |
| Rock Springs Capital Management LP | 2,513,916 | $79,917,390 | 1.90% |
| Artal Group S.A. | 1,638,858 | $52,099 | 1.62% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,493,470 | 0.75% |
| Avidity Partners Management LP | 501,200 | $15,933,148 | 0.56% |